Pacific Biosciences Of California (PACB) Cash & Current Investments (2010 - 2026)

Pacific Biosciences Of California's Cash & Current Investments history runs 17 years deep, the most recent figure standing at $276.0 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 19.57% year-over-year to $276.0 million; the TTM figure through Mar 2026 stood at $276.0 million (down 19.57% YoY), while the FY2025 annual figure was $279.5 million, down 28.32% from the prior year.
• Cash & Current Investments was $276.0 million for Q1 2026 at Pacific Biosciences Of California, down from $279.5 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $962.8 million in Q1 2022 to a low of $55.1 million in Q2 2025.
• Historically, Cash & Current Investments has averaged $442.5 million across 5 years, with a median of $354.1 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Cash & Current Investments slumped 87.97% in 2024, then jumped 279.62% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $772.3 million in 2022, then decreased by 18.24% to $631.4 million in 2023, then plunged by 38.24% to $389.9 million in 2024, then declined by 28.32% to $279.5 million in 2025, then decreased by 1.27% to $276.0 million in 2026.
• The last three Cash & Current Investments figures came in at $276.0 million (Q1 2026), $279.5 million (Q4 2025), and $298.7 million (Q3 2025), per Business Quant data.